In recent months, the principal bodies involved in drug reimbursement decisions in Canada have increased the transparency of their activities and are publishing more information on their respective websites. Quebec's Conseil du Médicament is now publishing reasons for its recommendations for coverage and, in September, began publishing information on the drugs which are currently under review. Recently, the Ontario Ministry of Health and Long Term Care also began issuing reports on the reasons for recommendations of that province's Committee to Evaluate Drugs. In a recent update, the Common Drug Review (CDR) has announced that it plans to expand its current practice of reporting summaries of recommendations and status of ongoing reviews by introducing these reports in future: a plain language version of recommendations and reasons of the Canadian Expert Drug Advisory Committee (CEDAC); the CDR clinical and pharmacoeconomic reports; and a summary of CEDAC's discussion relating to the drug.

For more information, please see: